Reducing Drug-Related Hospital Readmissions in Older Adults Through Clinical Pharmacist Support After Hospital Discharge
Led by Umeå University · Updated on 2024-12-20
700
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether involving clinical pharmacists in care transitions can lower drug-related hospital readmissions among patients aged over 75 years. This randomized controlled trial focuses on patients recently discharged from the hospital, assessing if pharmacist-led interventions improve medication management and patient outcomes during the critical post-discharge period.
Participants are divided into two groups one receives standard hospital medication review plus enhanced pharmacist services for 180 days after discharge, including biweekly medical chart reviews and phone calls within 7, 30, and 60 days to discuss medications and address potential issues with physicians. The control group receives standard hospital care, which may include medication review but no additional pharmacist follow-up.
Participants complete questionnaires on medication adherence and quality of life at baseline, 30 days, and 180 days. Researchers also review medical charts for readmissions and other health outcomes. The primary measurement is the time from hospital discharge to first drug-related readmission within 180 days. Secondary outcomes include readmission rates at 30 days, quality of life assessments, medication appropriateness, and mortality. Follow-up occurs at 30 and 180 days to monitor these outcomes.
CONDITIONS
Brief Title
Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People
Research Team
K
Kindstedt
M
Maria Gustafsson, Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Registered at one of ten pre-specified primary care health centers
Aged 75 years or older
You will not qualify if you...
Unable to communicate or do not speak Swedish
Scheduled for palliative care
Admitted due to intoxication by alcohol or non-prescription drug
Your Study Journey
Screening
Duration - Up to discharge from hospital
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Treatment
Duration - 180 days after discharge
Participants in the intervention group receive enhanced clinical pharmacist services including regular medical chart reviews and multiple phone interviews to discuss medications. The control group receives standard care which may include a medication review at the hospital.
Phone contacts at 7, 30, and 60 days; medical chart reviews every second week
Follow-up
Duration - 180 days after discharge
Participants report adherence and quality of life at 30 and 180 days after discharge. Additional data are collected from medical charts to monitor hospital readmissions and other outcomes.
2 visits for reporting adherence and quality of life (at 30 and 180 days)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Reducing Drug-Related Hospital Readmissions in Older Adults Through Clinical Pharmacist Support After Hospital Discharge
Families with Pride Program to Support Hispanic Sexual Minority Youth Aged 13 to 19
Preventing Depression and Drug Use by Improving Family Support and Acceptance
Online Family Support Program to Help Sexual and Gender Minority Youth of Color and Their Caregivers
Pilot Study to Reduce Mental Health and Social Challenges
Integrated Harm Reduction Program vs Usual Services for Black and Latinx People Who Use Drugs to Improve Service Use
Evaluating a Low Dead-space Syringe and Needle Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Evaluating an Enhanced eHealth Familias Unidas Program to Support Mental Health in Hispanic Youth
Randomized Trial in Pediatric Primary Care Clinics
Comparing Morning and Bedtime Dosing of Alisartan and Amlodipine for Treating Grade 1 Day-Night Hypertension in Adults Aged 18 to 70
Phase II Study of Nanoliposomal Irinotecan and XELOX Combined With Cadonilimab for First-Line Treatment of Advanced Pancreatic Ductal Adenocarcinoma
Project REACH Telehealth Program at Syringe Service Sites to Support People Who Use Drugs
Reducing Stigma in People Who Inject Drugs With HIV Using Rapid-Start Antiretroviral Therapy
A Pilot Study of the RS-ART Strategy in General and Prison Populations
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Investigating the effect of clinical pharmacist intervention in transitions of care on drug-related hospital readmissions among the elderly: study protocol for a randomised controlled trial.